WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006121207) METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTION OF ANTI-DSC2 ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/121207    International Application No.:    PCT/JP2006/309886
Publication Date: 16.11.2006 International Filing Date: 11.05.2006
IPC:
C07K 16/18 (2006.01), A61P 11/00 (2006.01)
Applicants: ONCOTHERAPY SCIENCE, INC. [JP/JP]; 2-1, Sakado 3-chome, Takatsu-ku, Kawasaki-shi, Kanagawa, 2130012 (JP) (For All Designated States Except US).
NAKATSURU, Shuichi [JP/JP]; (JP) (For US Only).
IWAMOTO, Takashi [JP/JP]; (JP) (For US Only).
YOSHIKAWA, Megumi [JP/JP]; (JP) (For US Only)
Inventors: NAKATSURU, Shuichi; (JP).
IWAMOTO, Takashi; (JP).
YOSHIKAWA, Megumi; (JP)
Agent: SHIMIZU, Hatsushi; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki 3000847 (JP)
Priority Data:
60/680,609 12.05.2005 US
Title (EN) METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTION OF ANTI-DSC2 ANTIBODY
(FR) PROCEDES POUR ENDOMMAGER DES CELLULES EN UTILISANT UNE FONCTION EFFECTRICE D’UN ANTICORPS ANTI-DSC2
Abstract: front page image
(EN)The present invention is based on the discovery that the cytoxicity of anti-desmocollin 2 (DSC2) antibodies can be used for treating various cancers including lung, colon, pancreatic, prostate, breast, gastric or liver cancers. Specifically, the present invention provides antibodies against DSC2 that have effector function. Furthermore, the present invention provides methods and pharmaceutical compositions that comprise anti-DSC2 antibody as an active ingredient for damaging DSC2-expressing cells via the effector function of the antibody.
(FR)La présente invention est basée sur la découverte que la cytotoxicité des anticorps anti-desmocolline 2 (DSC2) peut être utilisée pour le traitement de divers cancers comprenant les cancers du poumon, du colon, du pancréas, de la prostate, du sein, de l’estomac ou du foie. En particulier, la présente invention concerne des anticorps contre la DSC2 qui ont une fonction effectrice. De plus, la présente invention concerne des procédés et des compositions pharmaceutiques qui comprennent l’anticorps anti-DSC2 comme ingrédient actif pour endommager les cellules exprimant la DSC2 via la fonction effectrice de l’anticorps.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)